Transcode Therapeutics Inc. (RNAZ)

Overview

TransCode Therapeutics, Inc. is a pioneering ribonucleic acid (RNA) oncology company dedicated to the development and commercialization of therapeutic and diagnostic solutions for various forms of cancer. Established in 2016 and headquartered in Boston, Massachusetts, the company is at the forefront of leveraging RNA technology to target and manipulate cancer-causing genes, aiming to transform cancer treatment paradigms. Focused on addressing some of the most challenging aspects of cancer therapy, such as metastasis and resistance to current treatments, TransCode Therapeutics employs cutting-edge RNA-based technologies to develop innovative cancer therapies and diagnostics.

Products and Services

• TTX-MC138

TransCode Therapeutics' flagship therapeutic candidate, TTX-MC138, is designed to target microRNA-10b, identified as a master regulator of metastatic cell viability in several types of cancer, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas. By focusing on this microRNA, TTX-MC138 aims to provide a novel approach for treating cancers with high metastatic potential.

• TTX-siPDL1

This product is an siRNA (small interfering RNA)-based modulator targeting programmed death-ligand 1 (PD-L1). By modulating the expression of PD-L1, TTX-siPDL1 aims to enhance the immune system's ability to recognize and destroy cancer cells, offering a promising approach in the fight against cancer by mobilizing the patient's own immune responses.

• TTX-siLIN28B

Another key development in TransCode's portfolio is TTX-siLIN28B, an siRNA-based inhibitor targeting the RNA-binding protein LIN28B. LIN28B plays a crucial role in the development and progression of various cancers. TTX-siLIN28B seeks to address this by inhibiting LIN28B, thus offering a novel therapeutic strategy for combating cancers associated with this protein.

• TTX-RIGA

TTX-RIGA is an RNA-based agonist targeting the retinoic acid-inducible gene I (RIG-I). By activating RIG-I, TTX-RIGA aims to stimulate innate immunity within the tumor microenvironment, thereby enhancing the body's natural defenses against cancer cells. This approach represents an innovative strategy to modify the tumor microenvironment for therapeutic benefit.

• TTX-CRISPR

TransCode Therapeutics is also exploring the potential of CRISPR/Cas9 technology with TTX-CRISPR, a platform for the repair or elimination of cancer-causing genes directly inside tumor cells. Utilizing the precision of CRISPR/Cas9, TTX-CRISPR aims to offer targeted and personalized cancer therapies by editing the genes responsible for cancer progression.

• TTX-mRNA

The TTX-mRNA platform represents an mRNA-based approach for the development of cancer vaccines. By activating cytotoxic immune responses against tumor cells, TTX-mRNA vaccines aim to train the immune system to specifically target and eliminate cancer cells, offering a promising avenue for cancer prevention and treatment through immuno-oncology.